LONDON, ONTARIO--(Marketwire - May 28, 2010) - Sernova Corp. (TSX VENTURE: SVA) is pleased to announce that Dr. David White, chair of Sernova's Scientific Advisory Board, is presenting results from a key porcine diabetes study evaluating the safety and efficacy of the Cell Pouch System™.
Dr. White's podium presentation entitled "Development of a Cell Pouch to Form an Artificial Pancreas" is being presented in the "Artificial Organ Development Session" at the American Society of Artificial Internal Organs (ASAIO) 56th Annual Conference, Baltimore, MD, May 28th at 3:45 p.m.
The Cell Pouch System™ establishes a biological environment capable of preserving the functionality of therapeutic cells, allows for safe and long-term efficacious cell-based therapy and may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels.
The Cell Pouch System™ is a proprietary medical device, implanted below the skin, allowing for incorporation of tissue and microvasculature to form a subcutaneous tissue-engineered pancreas, establishing an environment for the survival and functionality of insulin-producing islets and other therapeutic cells.
The study supported by a $486,000 financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) which involves implantation of Sernova's novel medical device into diabetic pigs to establish device parameters and optimize performance will be used as part of the regulatory documentation in support of a future Phase I/II human clinical study.
Sernova believes that the Cell Pouch System™ has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.
According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.
Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System™ to provide a safe and efficacious environment for therapeutic cells and Sertolin™, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.
The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.